Formycon AG (0W4N.L)

40,95 +0,40 (+0,99%) Alla chiusura: 05:05PM BST

Formycon AG

Fraunhoferstrasse 15
Martinsried
Planegg 82152
Germany
49 89 864 667 100
https://www.formycon.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Stefan Glombitza	CEO & Member of Executive Board	N/D	N/D	1965
Dr. Friedrich-Wilhelm Steinweg	Co-Founder	N/D	N/D	N/D
Dr. Nicolas Combe Ph.D.	Co-Founder	N/D	N/D	N/D
Mr. Enno Spillner	CFO & Member of Management Board	N/D	N/D	1970
Dr. Andreas Seidl	Chief Scientific Officer & Member of Executive Board	N/D	N/D	1970
Ms. Nicola Mikulcik	Chief Business Officer & Member of Executive Board	N/D	N/D	1971
Sabrina Muller	Senior Manager of Corporate Communications & Investor Relations	N/D	N/D	N/D

Gli importi risalgono al giorno e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Formycon AG develops and markets biosimilar products in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema and myopic choroidal neovascularization under the Ranivisio, ONGAVIA, and CIMERLI names. The company's pipeline includes FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of chronic inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea, that treats neovascular age-related macular degeneration and serious retinal diseases that is in Phase III clinical trials. It is also developing FYB206, a biosimilar candidate for Keytruda, for the treatment of cancer; and FYB207, a SARS-CoV-2 blocker, an antiviral drug for the treatment of COVID-19. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.

Governance aziendale

L'ISS Governance QualityScore di Formycon AG al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.